Fact-Check Analysis
The claim makes a conceptually important distinction between two types of "wanting" or goal-directedness in biology: (1) non-teleonomic goal-directedness exhibited by individual cells through their internal control machinery, and (2) teleonomic goal-directedness exhibited by cancer tumors where drug resistance emerges from selection rather than internal control. However, the terminology as used is inverted relative to standard biological usage, and several nuances are missed or oversimplified.
1. Terminological Issues: "Teleonomic" vs. "Teleological"
In the philosophy of biology, teleology refers to explanations invoking final causes or purpose as a causal force in nature. Teleonomy was introduced by biologists such as Ernst Mayr to describe the appearance of purpose or goal-directedness in biological systems that arises from natural selection and evolved programs — not from any Aristotelian final causation [2,13]. As Page [2] explains, "purpose" in biology "carries no imputation of causation" [2]. Brandon [13] similarly clarifies that neo-Darwinian explanations of adaptations are teleological in a specific, non-mystical sense — they explain a trait's existence in terms of what it does (its effects on fitness) — and that this is distinct from non-teleological evolutionary explanations such as random drift [13].
The claim uses "non-teleonomic" to describe the cell's internal control-system behavior, but standard usage would characterize this differently. Cells have evolved internal regulatory architectures — signaling networks, feedback loops, gene regulatory circuits — that implement goal-directed behavior through mechanistic control processes. This is better described as cybernetically purposive (not involving final causes, but involving set-points, feedback, and control) [1,3]. Simon [1] explicitly treats cybernetic (feedback control) systems as a class of teleological systems — those that can be characterized by mathematical control theory, satisfy perturbation tests, and have independently testable feedback relations [1]. So under that framework, cells with internal control systems do count as teleological in the cybernetic sense — the claim's "non-teleonomic" label is misleading.
The claim then says the cancer tumor "wants" to develop resistance teleonomically — here the claim uses "teleonomic" in a way that partially aligns with standard usage (the appearance of purpose through selection). However, standard terminology would say that tumor-level phenomena like drug resistance arise through natural selection (a Darwinian process), which produces adapted outcomes that can be explained teleologically in the sense Brandon describes — by citing what they do (confer survival under therapy) [4–6,13]. So the claim's binary distinction (non-teleonomic for cells vs. teleonomic for tumors) does not map cleanly onto the established conceptual vocabulary.
2. Cellular Decision-Making as a Control System — Claim is Partially Correct
The claim correctly states that individual cells possess control architectures (sensors, actuators, control machinery) that enable adaptive, goal-directed behavior without invoking mysterious forces. A substantial literature from systems biology and control theory confirms this:
LeDuc et al. [3] provide a comprehensive framework ("BioMIMO") for understanding cells as feedback control systems with multiple inputs (chemical, mechanical, electrical, optical) and outputs, arguing that "control is intrinsic to biological organisms, whose cells are in a constant state of sensing and response" [3]. Cells implement proportional, derivative, and integral control through biochemical networks.
Araujo & Liotta [9] describe cell signaling networks as sophisticated control systems with feedback and feedforward loops that enable "simple complexity for sensitive robustness" — cells can filter noise, maintain homeostasis, and execute switch-like decisions (e.g., apoptosis) [9]. They explicitly note parallels between cellular networks and engineered control systems.
Wright et al. [7] demonstrate that even single-celled organisms like Stentor coeruleus exhibit non-associative learning (habituation) through stochastic switching between behavioral states, showing that cells maintain internal models of their environment updated by experience [7]. This goes beyond simple reflex.
Taborsky [8] argues from a Peircean semiotic perspective that biological entities at all levels (including cells) operate as "self-organizing informational systems" that make rational, pragmatic decisions about their environment, where decision-making is a triadic process of input-mediation-output [8]. This treats cells as intelligent agents without requiring a brain.
Thus, the claim that a cell can be said to "want" things (migrate, reproduce, apoptose) through its internal control machinery is supported — with the important caveat that this is a cybernetic/functional description, not ascription of consciousness.
3. Cancer Drug Resistance as an Evolutionary (Selection-Based) Phenomenon — Claim is Correct
The claim's second part — that cancer tumors "want" to develop resistance to chemotherapy only through selection (not through cellular control architecture) — is well-supported by the literature:
Gillies et al. [4] explicitly state that "all malignant cancers, whether inherited or sporadic, are fundamentally governed by Darwinian dynamics" and that therapy imposes "intense evolutionary selection pressures" leading inevitably to resistant populations [4]. They argue against a "teleological understanding of cancer" based solely on cataloguing genetic changes.
Gatenby & Brown [5] explain that resistance involves two steps: first, the deployment of resistance mechanisms (often pre-existing in the tumor), and second, the proliferation of resistant populations, which depends on Darwinian dynamics governed by fitness costs and benefits [5]. They note that "cancer cells can only adapt to immediate selection forces — they cannot anticipate future environmental conditions."
Greaves [6] emphasizes that "the emergence of drug resistance makes sense, and only makes sense, in an evolutionary context" [6]. Resistant mutants often exist before treatment and are selected by therapy.
Germain [12] provides a philosophical analysis showing cancer cells are "minimal Darwinian populations" but not "paradigmatic" ones — they undergo natural selection but are unlikely to produce complex, cumulative adaptations. Resistance typically involves one-shot changes (loss of a target, activation of pre-existing efflux pumps) rather than multi-step constructive evolution [12].
Thomas et al. [10] discuss how cancer adaptations can arise either through atavism (re-expression of ancient unicellular programs) or through de novo selection, noting that both mechanisms may operate [10]. Resistance often involves dormant capacities (e.g., ABC transporter efflux pumps) that were already present.
Arnal et al. [11] caution against excessive adaptationism, arguing that cancer cells are under selective pressure for only decades (not millions of years), so complex adaptive strategies seen in free-living organisms are unlikely to evolve in tumors [11].
4. Key Nuances and Corrections
While the core distinction is valid, several important nuances are missed:
a. The boundary is not absolute. Between the single cell and the tumor there is a spectrum. The tumor microenvironment (stromal cells, immune cells, vasculature) creates ecological niches that shape selection [4,10]. Some aspects of drug resistance involve cellular-level control mechanisms being activated (e.g., upregulation of efflux pumps via HIF-1α in response to hypoxia), which is a control-systems response, not purely selection [5]. Resistance is not purely an "all-or-none" selection phenomenon — it includes graded acclimatization [5].
b. The claim's terminology is inverted. Standard usage of "teleonomy" in biology (following Mayr) refers to evolved, program-based goal-directedness — which would apply to the cell's evolved control machinery, not the selection-level phenomenon. What the claim calls "non-teleonomic" (cellular control systems) is actually closer to what cybernetic theorists call teleological systems [1].
c. The claim that cellular decisions are "non-teleonomic" ignores their evolutionary origin. The reason cells have the control architectures they do (sensors, feedback loops, decision circuits) is that these were shaped by natural selection over evolutionary time — they are "teleonomic" in the sense of being programs that serve survival and reproduction [2,13]. The cell's "wanting" to migrate or apoptose is not a brute fact of control engineering but a product of eons of evolution that built those control systems.
d. Some cellular "decisions" are not purely internal. As highlighted by recent work on multicellular integration , cells in tissues are controlled at multiple ranges (short, medium, long) by the extracellular matrix and other cells — their "decisions" are often constrained by signals from the tissue architecture. This blurs the clean distinction between internal control and external selection.
e. The claim oversimplifies what "the tumor wants." Tumors are heterogeneous ecosystems with multiple subclones [4,6,12]. Drug resistance can emerge from pre-existing resistant clones (selection), from stress-induced mutagenesis (a cellular control response atavistically activated), or from phenotypic plasticity [10,11]. These mechanisms interact in complex ways.
Summary
| Aspect of Claim | Verdict | Explanation |
|---|---|---|
| Cells have control systems enabling goal-directed behavior | ✅ Supported | Extensive evidence from systems/control biology confirms cells operate as feedback control systems with sensors, actuators, and decision-making circuits [1,3,7,9] |
| Cellular "wanting" differs from tumor-level "wanting" | ✅ Supported in substance | Cellular behavior involves internal control machinery; tumor-level drug resistance arises from Darwinian selection on heterogeneous cell populations [4–6,12] |
| Terminology ("non-teleonomic" vs "teleonomic") | ⚠️ Confused/Inverted | Standard usage would consider cellular control architectures teleonomic (evolved programs); the cancer-selection process is explained teleologically (via natural selection) but does not involve a control system [1,2,13] |
| The dichotomy is clean and absolute | ❌ Oversimplified | Resistance involves both selection and cellular control responses; the tumor microenvironment creates a continuum between these levels [5,10,11] |
Bottom line: The claim correctly identifies a genuine and important distinction — individual cells make real-time decisions through internal control circuitry, while tumor-level phenomena like drug resistance emerge from population-level Darwinian selection, not from any tumor-level "controller." However, the terminology used is non-standard and partially inverted relative to the established biological-philosophical vocabulary of teleology and teleonomy. The dichotomy is also too sharp, as drug resistance involves both selection and cellular control mechanisms operating together. The statement is broadly correct in its core scientific insight but misleading in its terminological framing and oversimplified in its sharp binary distinction.
References
[1]Simon TW. Control systems and teleological systems. Behavioral Science. 1975;20(5):325-330DOI: 10.1002/bs.3830200505[2]Page LA. Teleology in biology: Who could ask for anything more? Zygon: Journal of Religion and Science. 2006;41(2)
DOI: 10.1111/j.1467-9744.2005.00747.x[3]LeDuc PR, Messner WC, Wikswo JP. How do control-based approaches enter into biology? Annual Review of Biomedical Engineering. 2011;13(1):369-396
DOI: 10.1146/annurev-bioeng-071910-124651[4]Gillies RJ, Verduzco D, Gatenby RA. Evolutionary dynamics of carcinogenesis and why targeted therapy does not work. Nature Reviews Cancer. 2012;12(7):487-493
DOI: 10.1038/nrc3298[5]Gatenby R, Brown J. The evolution and ecology of resistance in cancer therapy. Cold Spring Harbor Perspectives in Medicine. 2017;8(3):a033415
DOI: 10.1101/cshperspect.a033415[6]Greaves M. Nothing in cancer makes sense except…. BMC Biology. 2018;16(1)
DOI: 10.1186/s12915-018-0493-8[7]Wright CS, Joshi K, Iyer-Biswas S. Cellular learning: Habituation sans neurons in a unicellular organism. Current Biology. 2023;33(2):R61-R63
DOI: 10.1016/j.cub.2022.12.008[8]Taborsky E. Rational decision making in biological systems. Biosystems. 2022;217:104685
DOI: 10.1016/j.biosystems.2022.104685[9]Araujo RP, Liotta LA. A control theoretic paradigm for cell signaling networks: a simple complexity for a sensitive robustness. Current Opinion in Chemical Biology. 2006;10(1):81-87
DOI: 10.1016/j.cbpa.2006.01.002[10]Thomas F, Ujvari B, Renaud F, Vincent M. Cancer adaptations: Atavism, de novo selection, or something in between? BioEssays. 2017;39(8)
DOI: 10.1002/bies.201700039[11]Arnal A, Ujvari B, Crespi B, et al. Evolutionary perspective of cancer: myth, metaphors, and reality. Evolutionary Applications. 2015;8(6):541-544
DOI: 10.1111/eva.12265[12]Germain PL. Cancer cells and adaptive explanations. Biology & Philosophy. 2012;27(6):785-810
DOI: 10.1007/s10539-012-9334-2[13]Brandon RN. Biological teleology: Questions and explanations. Studies in History and Philosophy of Science Part A. 1981;12(2):91-105
DOI: 10.1016/0039-3681(81)90015-7
Yorumlar
Yorum Gönder